Ocular Therapeutix Reports Inducement Grant Under NASDAQ Rule
Ocular Therapeutix has appointed David W. Robinson as Global Chief Commercial Officer and granted him inducement equity awards effective...
No videos found.
INmune Bio’s Breakthrough Plan: 2025 Review, 2026 Goals
INmune Bio outlined two near-term catalysts and a tighter clinical focus in an investor update: a mid‑summer 2026 UK...
A Spotlight on Eurobio Scientific’s 2025 Revenue Growth
Eurobio Scientific reported full-year 2025 revenue of €168 million, up 9% year over year, with comparable pro forma growth...
Agios to Host Q4, Full Year 2025 Financial Results Call
Agios Pharmaceuticals will report fourth quarter and full-year 2025 results on February 12, 2026 via webcast—an otherwise routine earnings...
As US Research Recedes, What is Future of Biotech in Europe?
At the 2025 BIO Europe Summit, David Lowe, CEO of Ipsen, and Jeremy Levin, Chairman Emeritus of BIO, explored...
Novartis Streamlines Corporate Strategy to Accelerate High-Value Deal Execution
At 2025 BIO-Europe, it was clear that the pharmaceutical landscape had witnessed a significant shift in deal-making velocity, with...
BrightInsight Soars with Multi-Million Dollar AI Investment
BrightInsight has raised $13 million from Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners to...
New Partnership Delivers Arakoda® for Malaria Prevention
60 Degrees Pharmaceuticals has partnered with Runway Health to expand pre-departure access to Arakoda (tafenoquine), the only once-weekly, broad-spectrum...
Invivyd Partners with Lindsey Vonn on Disease Prevention
Invivyd has enlisted Olympic champion Lindsey Vonn for a national multimedia education campaign on antibodies and infectious disease prevention,...
Why 2026 is the Best of Times for Big Pharma and the Worst of Times for Biotech
In Washington, the ink was barely dry on a landmark domestic manufacturing deal for Pfizer. In San Diego, a...